Camp4 Therapeutics Corp

Overview

Compare with Marker Therapeutics, Inc., Radiopharm Theranostics Ltd or Kala Pharmaceuticals (United States), or pick any stock.

• TickerCAMP on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersWatertown, Massachusetts¹
• Incorporated inDE²
• Business address100 Talcott Avenue, Suite 201, Watertown, Ma 02472²
• Filer category, Emerging growth company²
• Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases. Our lead product candidate, CMP-002, has the potential to be the first disease-modifying therapy for the treatment of synaptic Ras GTPase activating protein 1 (“SYNGAP1”)-related disorder, or SYNGAP1, a severe developmental and epileptic encephalopathy (“DEE”) characterized by seizures, developmental delays, and cognitive impairments. SYNGAP1 is caused by haploinsufficiency of the SYNGAP1 gene, where mutation of one gene copy results in a reduction in functional SYNGAP protein levels of up to 50%. While we believe that it remains underdiagnosed, we estimate that there are approximately 21,000 individuals living with SYNGAP1 in th…³ From its latest annual report

Corporate structure

Camp4 Therapeutics Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Camp4 Therapeutics Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

We currently lease approximately 30,000 square feet of office and laboratory space in Cambridge, Massachusetts, and approximately 5,300 square feet of office and laboratory space in Boulder, Colorado. In December 2025, we amended our Cambridge lease and expect to vacate the Cambridge facility during 2026. We have entered into a new lease for approximately 44,000 square feet of office and laboratory space in Watertown, Massachusetts, which is expected to commence in 2026. We believe our facilities will be adequate for the foreseeable future and that suitable additional or substitute space will be available as and when needed.

Item 2 of the 10-K filed Mar 5, 2026.³

Leadership

Who has led Camp4 Therapeutics Corp, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerJosh Mandel-Brehm Oct 10, 2024 to now⁸
• Chief financial officerKelly Gold Oct 10, 2024 to now⁹

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive OfficerALFICA SEHGAL named Oct 29, 2021 to Jun 21, 2022²³
• Executive OfficerANN BARBIER named Jun 21, 2022²³
• Executive OfficerCALEB MOORE named Oct 29, 2021 to Jun 21, 2022²³
• Executive OfficerMICHELLE GATES named Oct 29, 2021 to Jun 21, 2022²³
• DirectorJORGE CONDE named Oct 29, 2021 to Jun 21, 2022²³
• DirectorMICHAEL HIGGINS named Oct 29, 2021 to Jun 21, 2022²³
• DirectorRICHARD YOUNG named Oct 29, 2021 to Jun 21, 2022²³
• DirectorSHAAN I. GANDHI named Oct 29, 2021 to Jun 21, 2022²³

Timeline

1. Sep 28, 20268-K Regulation FD disclosure; Other events²⁴
2. Aug 13, 20268-K Results of operations²⁵
3. Aug 4, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure²⁶
4. Jul 27, 20268-K Regulation FD disclosure; Other events²⁷
5. Jun 12, 20268-K Executive or director change; Shareholder vote²⁸
6. May 14, 20268-K Regulation FD disclosure²⁹
7. May 7, 20268-K Results of operations³⁰
8. Mar 24, 20268-K Executive or director change³¹
9. Mar 5, 20268-K Completed an acquisition or sale; Regulation FD disclosure³²
10. Jan 9, 20268-K Regulation FD disclosure³³
11. Dec 23, 20258-K Entered a material agreement; Ended a material agreement³⁴
12. Dec 18, 20258-K Entered a material agreement; Regulation FD disclosure³⁵
13. Oct 10, 2024New chief executive Josh Mandel-Brehm becomes CEO⁸

Calendar

Coming up

1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.55) a share, on Nov 6, 2025.³⁶

When it reported results

1. Aug 13, 2026Reported quarterly or annual results²⁵
2. May 7, 2026Reported quarterly or annual results³⁰
3. Nov 6, 2025Reported quarterly or annual results³⁷
4. Aug 14, 2025Reported quarterly or annual results³⁸
5. May 13, 2025Reported quarterly or annual results³⁹
6. Mar 27, 2025Reported quarterly or annual results⁴⁰
7. Nov 21, 2024Reported quarterly or annual results⁴¹

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

187 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 25 major events, 84 insider forms, 28 large holders, 2 private raises, 40 other. The latest 20:

1. Sep 28, 20268-K EDGAR
2. Sep 2, 20264 EDGAR
3. Aug 31, 2026SCHEDULE 13D/A EDGAR
4. Aug 31, 20264 EDGAR
5. Aug 26, 20264 EDGAR
6. Aug 21, 20264 EDGAR
7. Aug 19, 2026144 EDGAR
8. Aug 19, 20264 EDGAR
9. Aug 19, 2026SCHEDULE 13D/A EDGAR
10. Aug 14, 2026SCHEDULE 13G/A EDGAR
11. Aug 13, 202610-Q EDGAR
12. Aug 13, 20268-K EDGAR
13. Aug 12, 2026EFFECT EDGAR
14. Aug 12, 2026424B3 EDGAR
15. Aug 10, 2026SCHEDULE 13G EDGAR
16. Aug 6, 2026S-3 EDGAR
17. Aug 5, 2026SCHEDULE 13D/A EDGAR
18. Aug 5, 20264 EDGAR
19. Aug 5, 20264 EDGAR
20. Aug 5, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 20 buys and 6 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• 5AM Ventures VI, L.P.SCHEDULE 13D/A, 4 filings Oct 22, 2024 to Aug 31, 2026⁴²
• Polaris Management Co. VII, L.L.C.SCHEDULE 13D/A, 3 filings Oct 22, 2024 to Aug 19, 2026⁴³
• BALYASNY ASSET MANAGEMENT L.P.SCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 14, 2026⁴⁴
• Trails Edge Capital Partners, LPSCHEDULE 13G, 1 filing Aug 10, 2026⁴⁵
• Enavate Sciences GP, LLCSCHEDULE 13D/A, 4 filings Oct 22, 2024 to Mar 11, 2026⁴⁶
• Vivo Opportunity Fund Holdings, L.P.SCHEDULE 13G/A, 2 filings Sep 17, 2025 to Feb 13, 2026⁴⁷
• FMR LLCSCHEDULE 13G/A, 3 filings Oct 7, 2025 to Feb 5, 2026⁴⁸
• Janus Henderson Group Ltd.SCHEDULE 13G, 1 filing Jan 8, 2026⁴⁹
• Coastlands Capital LPSCHEDULE 13G/A, 2 filings Sep 16, 2025 to Dec 11, 2025⁵⁰
• AH Bio Fund I, L.P.SCHEDULE 13G/A, 2 filings Oct 22, 2024 to Nov 14, 2025⁵¹
• Northpond Ventures II, LPSCHEDULE 13G/A, 2 filings Oct 22, 2024 to Nov 14, 2025⁵²
• HARBOURVEST PARTNERS LLCSCHEDULE 13G/A, 2 filings May 14, 2025 to Oct 1, 2025⁵³

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Jun 3, 2022Raised $100.5 million in a private offering of equity Form D: 16 investors so far Form D
2. Mar 5, 2021Raised $45 million in a private offering of equity Form D: 7 investors so far Form D

SEC filer profile

How Camp4 Therapeutics Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARCamp4 Therapeutics Corp¹
• CIK0001736730
• Employer ID (EIN)81-1152476³
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company³
• Incorporated inDelaware³
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address100 Talcott Avenue, Suite 201, Watertown, MA 02472¹
• Phone617-651-8867¹
• Shares outstanding62,753,200 as of Aug 12, 2026⁷
• Public float$14.6M as of Jun 30, 2025³
• AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; no auditor attestation of internal control over financial reporting³
• On EDGAR sinceSep 25, 2018¹
• Filings189 in all: 4 (58), 8-K (25), 3 (23), SCHEDULE 13D/A (8), SCHEDULE 13G/A (8), SCHEDULE 13G (7), 10-Q (6), CORRESP (3)¹
  All 35 form types

  D (3), DRS/A (3), S-3 (3), S-8 (3), SC 13D (3), UPLOAD (3), 10-K (2), 3/A (2), 424B3 (2), 424B5 (2), ARS (2), DEF 14A (2), DEFA14A (2), DRSLTR (2), EFFECT (2), S-1/A (2), SC 13G (2), SEC STAFF LETTER (2), 144 (1), 4/A (1), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), DRS (1), FWP (1), S-1 (1)

• Latest filingsAnnual report (10-K) Mar 5, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Apr 23, 2026
  Latest 8-K (8-K) Sep 28, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 5, 2026 (Section 12(b) of the Exchange Act).³

Risk factors and legal proceedings

The risks Camp4 Therapeutics Corp names in Item 1A of its 10-K filed Mar 5, 2026: 73 risks under these headings, as written.³

• Risks Related to Our Financial Position and Need for Additional Capital
• We have incurred significant losses since our inception, have no products approved for sale and we expect to incur losses for the foreseeable future.
• We have never generated revenue from product sales and may never achieve or maintain profitability.
• We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our development programs, commercialization efforts or other operations.
• Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
• Risks Related to the Research and Development of Our Product Candidates
• We are early in our development efforts. Our product candidates are in varying stages of development. As a result, it will be many years before we commercialize a product candidate, if ever. If we are unable to identify and advance product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them, or experience significant delays in doing so, our business will be materially harmed.
• Our business is highly dependent on our lead product candidate, CMP-002, and we must complete clinical testing before we can seek regulatory approval and begin commercialization of any of our product candidates. If we are unable to obtain regulatory approval for, and successfully commercialize, our current product candidates, our business may be materially harmed, and such failure may affect the viability of any future product candidates.
• Our approach to the discovery and development of product candidates based on our RAP Platform is unproven, and we may not be successful in our efforts to develop and commercialize our product candidates and to identify and discover additional potential product candidates.
• Drug development is a lengthy and expensive process, and preclinical and clinical testing is uncertain as to the outcome. We may encounter substantial delays in the commencement, enrollment or completion of our clinical trials, or we may fail to demonstrate safety and effectiveness to the satisfaction of applicable regulatory authorities, which could prevent us from advancing or commercializing our product candidates on a timely basis, if at all.
• Interim, topline, and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials.

Legal proceedings

From time to time, we may be subject to legal proceedings. We are not currently a party to or aware of any proceedings that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors.

The opening of Item 3, Legal Proceedings.³